All In Biotech

Drug Trial Radar · NCT05907746

Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

13

Actual

Start

Nov 29, 2023

Primary completion

Oct 16, 2025

Study completion Jul 31, 2028

Sponsor

Sponsor type
NIH
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: People with GATA-binding factor 2 (GATA2) deficiency have a mutation on the GATA2 gene. This gene affects immune function. People with this disease are prone to serious infections; in time, they may develop blood cancers. A hematopoietic stem cell (HSC) transplant can cure GATA2 deficiency, but using stem cells donated by other people can cause serious side effects. Objective: To test a new drug (Briquilimab) to see if it can make HSC transplants safer. Eligibility: People aged 6 to 70 years who have GATA2 deficiency. Design: Participants will be screened. They will have a physical exam, with blood and urine tests. They will have tests of their heart and lung function. They may have a bone marrow biopsy: Their hip will be numbed; a large needle will be inserted to draw out tissue from inside the pelvis. Participants will have a central venous catheter placed in a vein of the neck or chest. This will be used to draw blood and administer drugs. Briquilimab will be given through the catheter about 11 days before the transplant. This is part of conditioning: preparing the body to receive the new stem cells. Conditioning also includes other medications and total body irradiation. Donor stem cells will be administered through the catheter. Participants will receive other approved drugs to help prevent side effects. Participants will stay in the hospital from the beginning of the conditioning until several weeks after the transplant. They will remain in the local area for 100 days after discharge; they will come to the clinic at least once a week during this time. Follow-up visits will continue for 3 years....

Conditions

  • GATA2
  • Immunodeficiency

Interventions

  • Mycophenolate MofetilDrug

    15 mg/kg intravenous (IV) three times per day starting on day +5 until approximately day +30 (+/- 2 days)

  • TacrolimusDrug

    0.02 mg/kg intravenous (IV) daily starting on day +5

  • Post-Transplant CyclophosphamideDrug

    50 mg/kg intravenous (IV) daily on days +3 and +4

  • Total Body IrradiationRadiation

    200 centigray (cGy) on day -1

  • Hematopoietic Cell TransplantProcedure

    Stem cell transplant on day 0

  • BriquilimabDrug

    Single 0.6 mg/kg intravenous (IV) infusion administered between days -13 and day -10

  • CyclophosphamideDrug

    14.5 mg/kg intravenous (IV) daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.

  • FludarabineDrug

    30 mg/m\^2 intravenous (IV) over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.

  • Bone Marrow BiopsyProcedure

    Screening ≤90 days.

  • Bone Marrow AspirateProcedure

    Screening ≤90 days.

  • 2D echoDiagnostic test

    Screening ≤90 days.

  • EKGDiagnostic test

    Screening ≤90 days.

  • PFT'sProcedure

    Screening ≤90 days.

  • CT scan of chest, abdomen and pelvisDiagnostic test

    Baseline ≤28 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Evaluable Participants With GATA-binding Factor 2 (GATA2) Deficiency With Sustained Donor Engraftment by 100 Days Post-transplant Reported Along With a Two-sided 90% Confidence IntervalTime frame: 100 days
  2. Percentage of Evaluable Participants With GATA-binding Factor 2 (GATA2) Deficiency With Sustained Donor Engraftment by 100 Days Post-transplant Reported Along With a Two-sided 95% Confidence IntervalTime frame: 100 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.